These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31820172)

  • 1. Monoclonal Antibodies: Past, Present and Future.
    Posner J; Barrington P; Brier T; Datta-Mannan A
    Handb Exp Pharmacol; 2019; 260():81-141. PubMed ID: 31820172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic human monoclonal antibodies in inflammatory diseases.
    Kotsovilis S; Andreakos E
    Methods Mol Biol; 2014; 1060():37-59. PubMed ID: 24037835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
    Bodey B; Siegel SE; Kaiser HE
    Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor inhibitors: clinical utility in autoimmune diseases.
    Willrich MA; Murray DL; Snyder MR
    Transl Res; 2015 Feb; 165(2):270-82. PubMed ID: 25305470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development.
    Mascelli MA; Zhou H; Sweet R; Getsy J; Davis HM; Graham M; Abernethy D
    J Clin Pharmacol; 2007 May; 47(5):553-65. PubMed ID: 17379759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Construction and characterization of monoclonal antibodies against the extracellular domain of B-lymphocyte antigen CD20 using DNA immunization method.
    Khademi F; Mostafaie A; Parvaneh S; Gholami Rad F; Mohammadi P; Bahrami G
    Int Immunopharmacol; 2017 Feb; 43():23-32. PubMed ID: 27939822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoid malignancies.
    Robak T; Robak E
    BioDrugs; 2011 Feb; 25(1):13-25. PubMed ID: 21090841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics of therapeutic monoclonal antibodies.
    Keizer RJ; Huitema AD; Schellens JH; Beijnen JH
    Clin Pharmacokinet; 2010 Aug; 49(8):493-507. PubMed ID: 20608753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies.
    Burlingham WJ; Jankowska-Gan E; DeVito-Haynes L; Fechner JH; Hogan KT; Claas FH; Mulder A; Wang X; Ferrone S
    J Immunol; 1998 Dec; 161(12):6705-14. PubMed ID: 9862700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.
    Loisel S; Ohresser M; Pallardy M; Daydé D; Berthou C; Cartron G; Watier H
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):34-42. PubMed ID: 17197192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors.
    Scott AM; Geleick D; Rubira M; Clarke K; Nice EC; Smyth FE; Stockert E; Richards EC; Carr FJ; Harris WJ; Armour KL; Rood J; Kypridis A; Kronina V; Murphy R; Lee FT; Liu Z; Kitamura K; Ritter G; Laughton K; Hoffman E; Burgess AW; Old LJ
    Cancer Res; 2000 Jun; 60(12):3254-61. PubMed ID: 10866319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms.
    Ordás I; Mould DR; Feagan BG; Sandborn WJ
    Clin Pharmacol Ther; 2012 Apr; 91(4):635-46. PubMed ID: 22357456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Characterization of Two Monoclonal Antibodies against the Same Epitope on B-Cell Receptor Associated Protein 31.
    Kim WT; Shin S; Hwang HJ; Kim MK; Jung HS; Park H; Ryu CJ
    PLoS One; 2016; 11(12):e0167527. PubMed ID: 27907150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic drug monitoring of monoclonal antibodies: Applicability based on their pharmacokinetic properties.
    Imamura CK
    Drug Metab Pharmacokinet; 2019 Feb; 34(1):14-18. PubMed ID: 30606646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
    Bodey B; Bodey B; Siegel SE; Kaiser HE
    Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies against the C(epsilon)mX domain of human membrane-bound IgE and their potential use for targeting IgE-expressing B cells.
    Chen HY; Liu FT; Hou CM; Huang JS; Sharma BB; Chang TW
    Int Arch Allergy Immunol; 2002 Aug; 128(4):315-24. PubMed ID: 12218370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous delivery of monoclonal antibodies: How do we get there?
    Viola M; Sequeira J; Seiça R; Veiga F; Serra J; Santos AC; Ribeiro AJ
    J Control Release; 2018 Sep; 286():301-314. PubMed ID: 30077735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of an extra immunoglobulin domain to two anti-rodent TNF monoclonal antibodies substantially increased their potency.
    Scallon B; Cai A; Radewonuk J; Naso M
    Mol Immunol; 2004 May; 41(1):73-80. PubMed ID: 15140577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.